Fed hikes again - an AI-Picked insurer is still cashing in

The Fed raised interest rates for the first time since 2023, triggering a 1.3% Dow decline, a 0.5% S&P 500 drop and a rise in the 10-year Treasury yield to about 5%. Performance diverged sharply across strategies: Tech Titans, Energy Elite and Healthcare Heroes continued to outperform, while Financial Fortresses lagged its benchmark by 3.02 percentage points as Cboe fell 12.09% and FactSet declined 9.50% this month. Chubb bucked the financial-sector weakness, rising 1.13% this month, supported by an estimated $1.2B increase in investment income per 100bp rate rise and a 7.2% quarterly EPS beat.

Analysis

The actionable split is not “insurance long / financials short,” but balance-sheet carry versus transaction-activity beta. CB can reinvest maturing float at higher yields while underwriting income provides a second earnings leg; FDS is more exposed to budget scrutiny and valuation-duration compression, while CBOE’s outcome hinges on whether rate and equity volatility produces durable derivatives volumes rather than a brief risk-off spike. The stated investment-income sensitivity should be treated as a company estimate: the relevant diligence is portfolio duration, runoff schedule, unrealized-loss position, and whether higher yields are accompanied by wider credit losses.

Over the next days, a broad de-risking tape can overwhelm CB’s carry narrative, particularly if financial ETFs are sold indiscriminately. Over 1-3 months, the key catalyst is insurer guidance on net investment income and reinvestment yields versus any deterioration in commercial P&C pricing or catastrophe losses; CB’s valuation can rerate only if the rate benefit reaches consensus EPS rather than remaining a long-duration accounting story. FDS faces a more immediate multiple risk if enterprise data/analytics spending decelerates, whereas CBOE could reverse sharply higher if elevated volatility persists and index/options volumes surprise positively.

Consensus appears too quick to classify CBOE as a simple rate loser. A sustained regime of higher realized volatility, wider dispersion and more hedging demand can improve transaction revenues, partially offsetting lower equity-market activity; this is a watch item, not yet a short, absent volume and net-revenue evidence. The cleaner contrarian risk to the CB thesis is a rapid growth scare: falling long yields would remove reinvestment upside while reserving and credit concerns could expand, leaving an insurer exposed to both lower carry expectations and a lower sector multiple over 6-18 months.

Key Decisions for Investors

• Initiate a 1-3 month long CB / short FDS pair, sized beta-neutral: CB has identifiable reinvestment-income upside while FDS has higher duration and corporate-spending sensitivity. Target 8-12% relative return; exit if the 10-year yield retraces below 4.5% or CB’s next net-investment-income outlook fails to move higher.
• Do not short CBOE solely on the rate shock. Set an earnings/volume alert: consider a tactical long only if options ADV, net revenue per contract and volatility-related volume remain elevated for 4-6 weeks; otherwise a CBOE short becomes more credible if lower cash-equity activity is not offset by derivatives growth.
• Use CB puts or reduce exposure ahead of catastrophe-heavy periods if the position is held beyond one quarter. A material reserve build, weakening commercial P&C pricing, or credit-spread widening would negate the higher-yield carry benefit faster than reinvestment income can accrue.
• Avoid broad XLF exposure as a rate-hike expression. Express the dispersion through insurers versus capital-markets/data businesses, since banks add deposit-beta and credit-loss risks that can dominate the yield effect.